top of page

Search Results

Results found for "Confo Therapeutics"

  • 📰 GPCR Weekly News, October 2 to 8, 2023

    This week's highlight: Congrats to our partner GPCR Therapeutics, on their expansion into fibrosis with selectivity Industry News Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets GPCR Therapeutics

  • 📰 GPCR Weekly News, August 14 to 20, 2023

    Congrats to the GPCR Therapeutics team for their recent paper in the American College of Clinical Pharmacology GPCR Symposium on 'GPCRs as Therapeutic Modalities'. and oligomerization Molecular Insights into GPCR Mechanisms for Drugs of Abuse Industry News 'GPCR Therapeutics Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic

  • 📰 GPCR Weekly News, September 11 to 17, 2023

    Kevin Wright on his new position as Director of Targeted and Immuno-oncology at GPCR Therapeutics, our GPCR Symposium on 'GPCRs as Therapeutic Modalities' with Richa Tyagi, Dr. Terry Kenakin, Dr. Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

  • 📰 GPCR Weekly News, May 1 to 7, 2023

    Industry News Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 Neurocrine Biosciences Reports First Quarter 2023 Financial Results Find Therapeutics welcomes critical, we cannot think about one size fits all” Dr Pina Cardarelli, Chief Scientific Officer, GPCR Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • 📰 GPCR Weekly News, July 24 to July 30, 2023

    This week's highlights: Driving Pharma Innovation in Oncology: Domain Therapeutics' Success Proven by GPCR Symposium on GPCRs as Therapeutic Modalities is on September 22nd. Industry News Omass Therapeutics Celebrates a Series of Recent Publications by their Scientists. Discover a New Way To Develop Drugs Without Side Effects Driving Pharma Innovation in Oncology: Domain Therapeutics

  • 📰 GPCR Weekly News, June 3 to June 9, 2024

    Adhesion GPCRs A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets Services and Cube Biotech Collaborate to Enhance Cryo-EM Enabled Gene to Structure Workflow Domain Therapeutics ACTH-Dependent Cushing’s Syndrome (ADCS) Septerna Presents Preclinical Data at ENDO 2024 Highlighting Therapeutic

  • Target Residence Time: The Hidden Driver of In Vivo Efficacy

    Modeling tools to understand how restricted diffusion  in tissues like tumors slows offset and improves therapeutic drug hiding in fat tissue may stay in the body for days, but if it never reaches the target site, the therapeutic

  • How Fast Does a Drug Work?

    essential for pipeline efficiency: How fast a ligand binds (k₁) and how long it stays bound (k₂)  can alter therapeutic When does onset rate dictate therapeutic onset, and when does offset rate predict duration?

  • 📰 GPCR Weekly News, June 26 to July 2, 2023

    GPCR Partner, Domain Therapeutics, for their nomination of the best-in-class CCR8 antibody candidate, History and function of the lactate receptor GPR81/HCAR1 in the brain: a putative therapeutic target G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics. Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening

  • 📰 GPCR Weekly News, June 24 to 30, 2024

    Bryan Roth and Brian Krumm for their study on Molecular glues as potential GPCR therapeutics Drs. breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects GPR56: A potential therapeutic via site-selective activation of mTOR GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics

  • 📰 GPCR Weekly News, August 7 to 13, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans Towards the convergent therapeutic Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program Structure Therapeutics

  • Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!

    appreciate the incredible versatility of GPCRs and how small molecules can affect their behavior for therapeutic Learn how to therapeutically exploit GPCRs (Physiology’s ‘Swiss Army Knife’) vast repertoire of ways Adjust ligand kinetics and tissue disposition for optimal therapeutic activity.

  • GPR108 is required for gambogic acid inhibiting NF-κB signaling in cancer

    Herein, we identified GPR108, a GPCR protein described in innate immune system, is a potential therapeutic Overall, our findings supported GPR108 as a promising therapeutic target of cancer, and provided a small

  • 📰 GPCR Weekly News, January 29 to February 4, 2024

    Xavier Leroy for his new role as CEO of GIO Therapeutics Dr. Molecular mechanism of GPCR spatial organization at the plasma membrane Industry News Launch of GIO Therapeutics , founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation AVROBIO and Tectonic Therapeutic Announce Merger Trevena Inc Elevates Barry

  • 📰 GPCR Weekly News, April 10 to 16, 2023

    Allosteric GPCR Drug Discovery from the 2nd Annual GPCRs-Targeted Drug Discovery Summit, Boston MA Pathios Therapeutics Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics presented 3 posters at AACR 2023 Exscientia presented a poster at AACR 2023 Pathios Therapeutics presented Swiss Biotech Day (April 24 - 25, 2023) ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • Allosteric modulation of GPCRs: From structural insights to in silico drug discovery

    orthosteric site), allosteric modulators offer new avenues for the regulation of GPCR function with potential therapeutic today, will facilitate structure-based discovery and development of allosteric modulators as novel therapeutic

  • Inverse Agonists, Lymphatic Fixes & β-arrestin Tricks

    Collaboration is the catalyst—let’s redefine what’s possible in GPCR-driven therapeutics.   

  • RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany...

    So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic

  • Nanobodies: New Dimensions in GPCR Signaling Research

    the development of more selective drugs capable of modulating specific signaling pathways, improving therapeutic This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending its conformation, protects the Schiff base, and prevents protein degradation, potentially offering therapeutic Nanobodies: A Review of Generation, Diagnostics and Therapeutics.

  • Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System

    tools used to manipulate GPCR activity in an orthosteric site-independent manner to compounds with therapeutic development for each receptor, as well as the structural, signaling, pathophysiologic consequences, and therapeutic

  • 📰 GPCR Weekly News, March 13 to 19, 2023

    GPCRs in Oncology and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists Reviews, GPCRs, and more The leukotriene B4 receptors BLT1 and BLT2 as potential therapeutic targets. It Will Participate For H1 2023 Learn more about Exscientia new pipeline candidate, EXS74539 Domain Therapeutics women-men professional equality index Octant introduces Hypatia, their New Robotic Drug Hunter GPCR Therapeutics

  • 📰 GPCR Weekly News, May 29 to June 4, 2023

    GPCR Activation and Signaling Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides Industry News Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions Domain Therapeutics' Nomination of DT-9045: A Groundbreaking NAM for Immunooncology Structure Therapeutics to Present at Jefferies Healthcare

  • 📰 GPCR Weekly News, June 19 to 25, 2023

    GPCR Partner, GPCR Therapeutics, for passing the Technology Evaluation process for listing on the KOSDAQ GPCR Therapeutics passes the Technology Evaluation process for listing on KOSDAQ. function" (June 28 - 30, 2023) FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics

  • Ben Clements on Rescuing Opioids with GPCR Modulators

    His work highlights how foundational GPCR science can drive therapeutic innovation.

  • Targeting Intracellular Allosteric Sites in GPCRs

    other GPCR-regulated systems such as free fatty acid receptors (FFARs), now regarded as targets for therapeutic and β-arrestin coupling, enabling the development of biased agonists and antagonists with distinct therapeutic Allosteric modulation is gaining prominence in GPCR therapeutics, with the discovery of an intracellular Biased allosteric modulators can enhance the safety and efficacy of GPCR-targeted therapeutics by selectively

  • 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024

    Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder, Maxion Therapeutics ) – BioLeader Interview Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK

  • 📰 GPCR Weekly News, May 27 to June 2, 2024

    tunes mGlu5 receptor function, impacting synaptic transmission Orphan receptor GPR88 as a potential therapeutic the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies Industry News Structure Therapeutics

  • 📰 GPCR Weekly News, August 21 to 27, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities'. neutrophil chemoattractant Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics

  • 📰 GPCR Weekly News, January 1 to 7, 2024

    Congratulations to Domain Therapeutics for appointing Michael Gottlieb as Chairman and Dr. of GPCRs in various states Reviews, GPCRs, and more G Protein-coupled Receptors (GPCRs) as Potential Therapeutics modulate engagement of CCR5 by chemokines by removing key electrostatic interactions Industry News Domain Therapeutics

  • 📰 GPCR Weekly News, April 15 to 21, 2024

    GPCRs in Oncology and Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Deorphanization of G Protein Coupled Receptors (GPCRs): a historical perspective Industry News Addex Therapeutics at the 19th Biopharma Drug Discovery Nexus Salipro Biotech will participate in BioKorea2024 Domain Therapeutics

bottom of page